Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Liabilities and Shareholders Equity (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $322.0 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 20.18% year-over-year to $322.0 million; the TTM value through Sep 2025 reached $1.3 billion, up 179.64%, while the annual FY2024 figure was $370.0 million, 442.63% up from the prior year.
  • Liabilities and Shareholders Equity reached $322.0 million in Q3 2025 per ZBIO's latest filing, up from $293.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $403.4 million in Q3 2024 and bottomed at $68.2 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $298.4 million, with a median of $327.9 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 442.63% in 2024, then fell 20.18% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $68.2 million in 2023, then skyrocketed by 442.63% to $370.0 million in 2024, then decreased by 12.96% to $322.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $322.0 million in Q3 2025, $293.1 million in Q2 2025, and $333.8 million in Q1 2025.